Contact
searchSearch
HMP Global
Login
Quiz

Vorasidenib for Previously Untreated Patients With Residual or Recurrent Grade 2 IDH-Mutant Glioma

08/19/2025

Related Content

News
NEO100-01 Meets Primary End Point, Supporting Further Development in IDH1-Mutant Glioma
08/31/2026
Emily Estrada
Topline results from the phase 2a NEO100-01 trial showed that intranasal NEO100 achieved a 48.9% 6-month progression-free survival rate in patients with recurrent IDH1-mutant high-grade glioma, significantly exceeding the prespecified 20%...
Topline results from the phase 2a NEO100-01 trial showed that intranasal NEO100 achieved a 48.9% 6-month progression-free survival rate in patients with recurrent IDH1-mutant high-grade glioma, significantly exceeding the prespecified 20%...
Topline results from the phase...
08/31/2026
Oncology
News
Safusidenib Demonstrates Durable Responses and Prolonged Disease Control in Grade 2 IDH1-Mutant Glioma
07/21/2026
Emily Estrada
Updated findings from the phase 2 J201 trial demonstrated that safusidenib, a selective mutant IDH1 inhibitor, produced durable responses and prolonged disease control in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant...
Updated findings from the phase 2 J201 trial demonstrated that safusidenib, a selective mutant IDH1 inhibitor, produced durable responses and prolonged disease control in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant...
Updated findings from the phase...
07/21/2026
Oncology
News
Dose-Escalation Study Supports Phase 2 Development of BMS-986205 Plus Radiotherapy and Nivolumab in Glioblastoma
07/09/2026
Stephanie Holland
Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...
Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...
Results from a phase 1 trial...
07/09/2026
Oncology
News
MRI-Guided Adaptive Radiotherapy Enables Margin Reduction in Adult Patients With Glioblastoma
06/30/2026
Emily Estrada
Results from the phase 2 UNITED trial demonstrated that MRI-guided adaptive radiotherapy with reduced treatment margins was associated with a low rate of marginal failure in adult patients with glioblastoma.
Results from the phase 2 UNITED trial demonstrated that MRI-guided adaptive radiotherapy with reduced treatment margins was associated with a low rate of marginal failure in adult patients with glioblastoma.
Results from the phase 2 UNITED...
06/30/2026
Oncology

Recent News

FDA Approval
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer
09/18/2026
Stephanie Holland
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase...
09/18/2026
Oncology
FDA Alerts
FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer
09/17/2026
Emily Estrada
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental...
09/17/2026
Oncology
News
Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma
09/17/2026
Emily Estrada
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE...
09/17/2026
Oncology
News
Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation
09/17/2026
Emily Estrada
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial...
09/17/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer
09/16/2026
Stephanie Holland
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3...
09/16/2026
Oncology
FDA Alerts
FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access
09/16/2026
Stephanie Holland
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing...
09/16/2026
Oncology
News
Tarlatamab Plus Durvalumab Improves Survival as First-Line Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
09/15/2026
Emily Estrada
Topline results from the phase 3 DeLLphi-305 trial showed that adding tarlatamab to durvalumab significantly improved overall and progression-free survival compared with durvalumab alone as first-line maintenance therapy for patients with...
Topline results from the phase 3 DeLLphi-305 trial showed that adding tarlatamab to durvalumab significantly improved overall and progression-free survival compared with durvalumab alone as first-line maintenance therapy for patients with...
Topline results from the phase 3...
09/15/2026
Oncology
News
GLP-1 Receptor Agonists Linked to Lower Mortality and Thrombotic Complications in Essential Thrombocythemia
09/15/2026
Emily Estrada
Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...
Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...
Real-world findings associated...
09/15/2026
Oncology
News
Sustained Ropeginterferon Alfa-2b Treatment Deepens Molecular Responses in High-Risk Essential Thrombocythemia
09/15/2026
Emily Estrada
Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...
Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...
Extended results from the phase...
09/15/2026
Oncology
News
Ropeginterferon Alfa-2b Achieves Increasing Complete Hematologic Response Rates With Longer Treatment in Patients With Myeloproliferative Neoplasms
09/15/2026
Emily Estrada
Results from a real-world study demonstrated that ropeginterferon alfa-2b produced increasing complete hematologic responses over time in patients with myeloproliferative neoplasms, including essential thrombocythemia, with tolerability...
Results from a real-world study demonstrated that ropeginterferon alfa-2b produced increasing complete hematologic responses over time in patients with myeloproliferative neoplasms, including essential thrombocythemia, with tolerability...
Results from a real-world study...
09/15/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use